Program
Dextromethorphan/Bupropion Tablet AXS-05
Also written as “AXS-05”, “AXS-05 (dextromethorphan-bupropion)” and “AXS-05 (dextromethorphan and bupropion) oral tablets”.
Its studies are mostly in Alzheimer Disease · Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant · Smoking Cessation · Depression, led by Axsome Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Axsome Therapeutics | 142 open or running | phase 4since Jan 16, 2024 | Apr 5, 2016 | Dec 2027phase 3 · NCT07766655 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 5, 2016First study: phase 3 study in Depressive Disorder, MajorFirst studyNCT02741791 · 312 enrolled · United States
- Jul 20, 2017Phase 3 study in Alzheimer DiseaseNCT03226522 · 366 enrolled · United States, Australia
- Jun 20, 2018Phase 2 study in Depressive Disorder, MajorNCT03595579 · 97 enrolled · United States
- Jul 11, 20192 phase 3 studiesNCT04019704, NCT04039022
- Oct 7, 2020Phase 2 study in Depressive Disorder, Treatment-ResistantNCT04608396 · 44 enrolled · United States
- Nov 12, 2020Phase 2 study in Depressive Disorder, Treatment-ResistantNCT04634669 · 181 enrolled · United States
- Mar 5, 2021Phase 3 study in Alzheimer DiseaseNCT04797715 · 178 enrolled · United States, Canada
- Jun 24, 2021Phase 3 study in Alzheimer DiseaseNCT04947553 · 456 enrolled · United States, Canada, Puerto Rico
- Jul 12, 2021Phase 2 study in Depressive Disorder, MajorNCT04971291 · 312 enrolled · United States
- Sep 23, 2022Phase 3 study in Alzheimer DiseaseNCT05557409 · 408 enrolled · United States, Puerto Rico
- Jan 16, 2024Phase 4 study in Depressive Disorder, MajorNCT06223880 · 350 planned · United States
- Dec 12, 2024Phase 3 study in Alzheimer DiseaseNCT06736509 · 139 enrolled · United States, Puerto Rico
- Aug 11, 2026Phase 3 study in Smoking CessationNCT07766655 · 705 planned · United States
Ahead
- Dec 2027Primary completion: phase 3 study in Smoking CessationNCT07766655
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07766655Smoking Cessation · United States | 3 | Recruiting | Dec 2027 | 705 |
| NCT06736509Alzheimer Disease · United States, Puerto Rico | 3 | Terminated | Feb 17, 2025 | 139 |
| NCT06223880Depressive Disorder, Major · United States | 4 | Recruiting | Mar 2026 | 350 |
| NCT05557409Alzheimer Disease · United States, Puerto Rico | 3 | Completed | Nov 21, 2024 | 408 |
| NCT04971291Depressive Disorder, Major · United States | 2 | UNKNOWN | Jul 2021 | 312 |
| NCT04947553Alzheimer Disease · United States, Canada, Puerto Rico | 3 | Completed | Dec 3, 2024 | 456 |
| NCT04797715Alzheimer Disease · United States, Canada | 3 | Completed | Nov 21, 2022 | 178 |
| NCT04634669Depressive Disorder, Treatment-Resistant · United States | 2 | Terminated | Feb 18, 2022 | 181 |
| NCT04608396Depressive Disorder, Treatment-Resistant · United States | 2 | Completed | Jul 30, 2021 | 44 |
| NCT04039022Depressive Disorder, Major · United States | 3 | Completed | Oct 23, 2020 | 876 |
| NCT04019704Depression · United States | 3 | Completed | Nov 26, 2019 | 327 |
| NCT03595579Depressive Disorder, Major · United States | 2 | Completed | Jan 7, 2019 | 97 |
| NCT03226522Alzheimer Disease · United States, Australia | 3 | Completed | Apr 17, 2020 | 366 |
| NCT02741791Depressive Disorder, Major · United States | 3 | Completed | Mar 20, 2020 | 312 |
How it is read
Names in the registry
- “AXS-05”, 9 entries
- “AXS-05 (dextromethorphan-bupropion)”, 4 entries
- “AXS-05 (dextromethorphan and bupropion) oral tablets”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 5 studies
- Depressive Disorder, Major, 5 studies
- Depressive Disorder, Treatment-Resistant, 2 studies
- Smoking Cessation, 1 study
- Depression, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.